In human myeloid leukemia cell KBM-5 and lung adenocarcinoma cell H1299 [36], evodiamine inhibits the activation of NF-κB by various carcinogens and inflammatory agents, and causes the reduction of NF-κB -regulated gene products including mediating proliferation (cyclin D1 and c-Myc), antiapoptosis (Survivin and tumor necrosis factor receptor associated factor 1), immunomodulation (chemokines and interleukins) and metastasis (ICAM-1and MMP-9), whereas in human melanoma A375-S2 cells [29], evodiamine activates NF-κB and causes a rapid increase in iNOS expression. Here, NFKB1 is linked to lung adenocarcinoma.